Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123


Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

Sagnella SM, Trieu J, Brahmbhatt H, MacDiarmid JA, MacMillan A, Whan RM, Fife CM, McCarroll JA, Gifford AJM, Ziegler DS, Kavallaris M.

Mol Cancer Ther. 2018 Feb 28. pii: molcanther.0738.2017. doi: 10.1158/1535-7163.MCT-17-0738. [Epub ahead of print]


Water Soluble Antioxidant Dextran-Quercetin Conjugate with Potential Anticancer Properties.

Oliver S, Yee E, Kavallaris M, Vittorio O, Boyer C.

Macromol Biosci. 2018 Feb 7. doi: 10.1002/mabi.201700239. [Epub ahead of print]


Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells.

Yee EMH, Brandl MB, Pasquier E, Cirillo G, Kimpton K, Kavallaris M, Kumar N, Vittorio O.

Sci Rep. 2017 Aug 9;7(1):7638. doi: 10.1038/s41598-017-07452-w.


Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells.

Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC.

Cell Cycle. 2017 Jul 27:0. doi: 10.1080/15384101.2017.1356512. [Epub ahead of print]


An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.

Parker AL, Teo WS, McCarroll JA, Kavallaris M.

Int J Mol Sci. 2017 Jul 4;18(7). pii: E1434. doi: 10.3390/ijms18071434. Review.


Tuneable catechin functionalisation of carbohydrate polymers.

Oliver S, Jofri A, Thomas DS, Vittorio O, Kavallaris M, Boyer C.

Carbohydr Polym. 2017 Aug 1;169:480-494. doi: 10.1016/j.carbpol.2017.04.032. Epub 2017 Apr 23.


The RhoGAP protein ARHGAP18/SENEX localizes to microtubules and regulates their stability in endothelial cells.

Lovelace MD, Powter EE, Coleman PR, Zhao Y, Parker A, Chang GH, Lay AJ, Hunter J, McGrath AP, Jormakka M, Bertolino P, McCaughan G, Kavallaris M, Vadas MA, Gamble JR.

Mol Biol Cell. 2017 Apr 15;28(8):1066-1078. doi: 10.1091/mbc.E16-05-0285. Epub 2017 Mar 1.


Nanoparticles for radiooncology: Mission, vision, challenges.

Kunz-Schughart LA, Dubrovska A, Peitzsch C, Ewe A, Aigner A, Schellenburg S, Muders MH, Hampel S, Cirillo G, Iemma F, Tietze R, Alexiou C, Stephan H, Zarschler K, Vittorio O, Kavallaris M, Parak WJ, Mädler L, Pokhrel S.

Biomaterials. 2017 Mar;120:155-184. doi: 10.1016/j.biomaterials.2016.12.010. Epub 2016 Dec 14. Review.


Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.

Sharbeen G, McCarroll J, Liu J, Youkhana J, Limbri LF, Biankin AV, Johns A, Kavallaris M, Goldstein D, Phillips PA.

Neoplasia. 2016 Dec;18(12):753-764. doi: 10.1016/j.neo.2016.10.011. Epub 2016 Nov 24.


The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.

Liu PY, Sokolowski N, Guo ST, Siddiqi F, Atmadibrata B, Telfer TJ, Sun Y, Zhang L, Yu D, Mccarroll J, Liu B, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, Liu T.

Oncotarget. 2016 Nov 29;7(48):79217-79232. doi: 10.18632/oncotarget.12640.


6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.

Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.

Mol Cancer Ther. 2017 Jan;16(1):3-15. doi: 10.1158/1535-7163.MCT-16-0325. Epub 2016 Oct 19.


Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth.

Vittorio O, Brandl M, Cirillo G, Kimpton K, Hinde E, Gaus K, Yee E, Kumar N, Duong H, Fleming C, Haber M, Norris M, Boyer C, Kavallaris M.

Oncotarget. 2016 Jul 26;7(30):47479-47493. doi: 10.18632/oncotarget.10201.


Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Fife CM, Sagnella SM, Teo WS, Po'uha ST, Byrne FL, Yeap YY, Ng DC, Davis TP, McCarroll JA, Kavallaris M.

Oncogene. 2017 Jan 26;36(4):501-511. doi: 10.1038/onc.2016.220. Epub 2016 Jun 20.


A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo.

Teo J, McCarroll JA, Boyer C, Youkhana J, Sagnella SM, Duong HT, Liu J, Sharbeen G, Goldstein D, Davis TP, Kavallaris M, Phillips PA.

Biomacromolecules. 2016 Jul 11;17(7):2337-51. doi: 10.1021/acs.biomac.6b00185. Epub 2016 Jun 28.


Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study.

Pasquier E, André N, Street J, Chougule A, Rekhi B, Ghosh J, Philip DSJ, Meurer M, MacKenzie KL, Kavallaris M, Banavali SD.

EBioMedicine. 2016 Apr;6:87-95. doi: 10.1016/j.ebiom.2016.02.026. Epub 2016 Feb 17.


βIII-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells.

Parker AL, Turner N, McCarroll JA, Kavallaris M.

Carcinogenesis. 2016 Aug;37(8):787-798. doi: 10.1093/carcin/bgw058. Epub 2016 May 4.


Gamma-actin is involved in regulating centrosome function and mitotic progression in cancer cells.

Po'uha ST, Kavallaris M.

Cell Cycle. 2015;14(24):3908-19. doi: 10.1080/15384101.2015.1120920.


Macromolecular Hydrogen Sulfide Donors Trigger Spatiotemporally Confined Changes in Cell Signaling.

Ercole F, Mansfeld FM, Kavallaris M, Whittaker MR, Quinn JF, Halls ML, Davis TP.

Biomacromolecules. 2016 Jan 11;17(1):371-83. doi: 10.1021/acs.biomac.5b01469. Epub 2015 Dec 23.


Analyses of Tumor Burden In Vivo and Metastasis Ex Vivo Using Luciferase-Expressing Cancer Cells in an Orthotopic Mouse Model of Neuroblastoma.

Byrne FL, McCarroll JA, Kavallaris M.

Methods Mol Biol. 2016;1372:61-77. doi: 10.1007/978-1-4939-3148-4_5.


The endocytic pathway and therapeutic efficiency of doxorubicin conjugated cholesterol-derived polymers.

Sevimli S, Sagnella S, Macmillan A, Whan R, Kavallaris M, Bulmus V, Davis TP.

Biomater Sci. 2015 Feb;3(2):323-35. doi: 10.1039/c4bm00224e. Epub 2014 Sep 25.


Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.


γ-Actin plays a key role in endothelial cell motility and neovessel maintenance.

Pasquier E, Tuset MP, Sinnappan S, Carnell M, Macmillan A, Kavallaris M.

Vasc Cell. 2015 Feb 6;7:2. doi: 10.1186/s13221-014-0027-2. eCollection 2015.


Correction to "effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers".

Boyer C, Teo J, Phillips P, Erlich RB, Sagnella S, Sharbeen G, Dwarte T, Duong HT, Goldstein D, Davis TP, Kavallaris M, McCarroll J.

Mol Pharm. 2015 Mar 2;12(3):1004. doi: 10.1021/acs.molpharmaceut.5b00092. Epub 2015 Feb 18. No abstract available.


Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.

McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, Liu J, Phillips PA, Rana TM, Kavallaris M.

Oncotarget. 2015 May 20;6(14):12020-34.


βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer.

McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan M, Johns AL, Biankin AV, Kavallaris M, Phillips PA.

Oncotarget. 2015 Feb 10;6(4):2235-49.


Graphene oxide - gelatin nanohybrids as functional tools for enhanced Carboplatin activity in neuroblastoma cells.

Makharza S, Vittorio O, Cirillo G, Oswald S, Hinde E, Kavallaris M, Büchner B, Mertig M, Hampel S.

Pharm Res. 2015 Jun;32(6):2132-43. doi: 10.1007/s11095-014-1604-z. Epub 2014 Dec 24.


TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.

McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH, Shum MS, Byrne FL, Kavallaris M.

Cancer Res. 2015 Jan 15;75(2):415-25. doi: 10.1158/0008-5472.CAN-14-2740. Epub 2014 Nov 20.


Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes.

Eiffe E, Pasquier E, Kavallaris M, Herbert C, StC Black D, Kumar N.

Bioorg Med Chem. 2014 Oct 1;22(19):5182-93. doi: 10.1016/j.bmc.2014.08.010. Epub 2014 Aug 17.


Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.

Brandl MB, Pasquier E, Li F, Beck D, Zhang S, Zhao H, Kavallaris M, Wong ST.

Mol Oncol. 2014 Dec;8(8):1548-60. doi: 10.1016/j.molonc.2014.06.007. Epub 2014 Jun 19.


Microtubules and their role in cellular stress in cancer.

Parker AL, Kavallaris M, McCarroll JA.

Front Oncol. 2014 Jun 18;4:153. doi: 10.3389/fonc.2014.00153. eCollection 2014. Review.


Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, Liu B, Bell JL, Zhang XD, Milazzo G, Cheung BB, Fox A, Swarbrick A, Hüttelmaier S, Kavallaris M, Perini G, Mattick JS, Dinger ME, Liu T.

J Natl Cancer Inst. 2014 Jun 6;106(7). pii: dju113. doi: 10.1093/jnci/dju113. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1):doi/10.1093/jnci/dju359.


Drug delivery: beyond active tumour targeting.

Sagnella SM, McCarroll JA, Kavallaris M.

Nanomedicine. 2014 Aug;10(6):1131-7. doi: 10.1016/j.nano.2014.04.012. Epub 2014 May 10. Review.


Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

McCarroll JA, Naim S, Sharbeen G, Russia N, Lee J, Kavallaris M, Goldstein D, Phillips PA.

Front Physiol. 2014 Apr 9;5:141. doi: 10.3389/fphys.2014.00141. eCollection 2014. Review.


Movers and shakers: cell cytoskeleton in cancer metastasis.

Fife CM, McCarroll JA, Kavallaris M.

Br J Pharmacol. 2014 Dec;171(24):5507-23. doi: 10.1111/bph.12704. Epub 2014 Jul 2. Review. Erratum in: Br J Pharmacol. 2017 Jan;174(1):116.


Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer.

McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA.

Front Physiol. 2014 Jan 24;5:2. doi: 10.3389/fphys.2014.00002. eCollection 2014. Review.


Magnetic catechin-dextran conjugate as targeted therapeutic for pancreatic tumour cells.

Vittorio O, Voliani V, Faraci P, Karmakar B, Iemma F, Hampel S, Kavallaris M, Cirillo G.

J Drug Target. 2014 Jun;22(5):408-15. doi: 10.3109/1061186X.2013.878941. Epub 2014 Jan 16.


Dextran-based doxorubicin nanocarriers with improved tumor penetration.

Sagnella SM, Duong H, MacMillan A, Boyer C, Whan R, McCarroll JA, Davis TP, Kavallaris M.

Biomacromolecules. 2014 Jan 13;15(1):262-75. doi: 10.1021/bm401526d. Epub 2013 Dec 18.


Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.

Kim PY, Tan O, Diakiw SM, Carter D, Sekerye EO, Wasinger VC, Liu T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, Cheung BB.

J Proteomics. 2014 Jan 16;96:1-12. doi: 10.1016/j.jprot.2013.10.032. Epub 2013 Nov 4.


Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release.

Basuki JS, Duong HT, Macmillan A, Erlich RB, Esser L, Akerfeldt MC, Whan RM, Kavallaris M, Boyer C, Davis TP.

ACS Nano. 2013 Nov 26;7(11):10175-89. doi: 10.1021/nn404407g. Epub 2013 Oct 16.


Assessment of cholesterol-derived ionic copolymers as potential vectors for gene delivery.

Sevimli S, Sagnella S, Kavallaris M, Bulmus V, Davis TP.

Biomacromolecules. 2013 Nov 11;14(11):4135-49. doi: 10.1021/bm4013088. Epub 2013 Oct 30.


β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.

Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M.

Br J Cancer. 2013 Jun 25;108(12):2485-94. doi: 10.1038/bjc.2013.205. Epub 2013 May 21.


Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.

Boyer C, Teo J, Phillips P, Erlich RB, Sagnella S, Sharbeen G, Dwarte T, Duong HT, Goldstein D, Davis TP, Kavallaris M, McCarroll J.

Mol Pharm. 2013 Jun 3;10(6):2435-44. doi: 10.1021/mp400049e. Epub 2013 May 6. Erratum in: Mol Pharm. 2015 Mar 2;12(3):1004.


TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization.

Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB.

Cell Cycle. 2013 Mar 15;12(6):889-98. doi: 10.4161/cc.23825. Epub 2013 Feb 19.


RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.

Byrne FL, Yang L, Phillips PA, Hansford LM, Fletcher JI, Ormandy CJ, McCarroll JA, Kavallaris M.

Oncogene. 2014 Feb 13;33(7):882-90. doi: 10.1038/onc.2013.11. Epub 2013 Feb 11.


Partial depletion of gamma-actin suppresses microtubule dynamics.

Po'uha ST, Honore S, Braguer D, Kavallaris M.

Cytoskeleton (Hoboken). 2013 Mar;70(3):148-60. doi: 10.1002/cm.21096. Epub 2013 Jan 17.


Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers.

Duong HT, Kamarudin ZM, Erlich RB, Li Y, Jones MW, Kavallaris M, Boyer C, Davis TP.

Chem Commun (Camb). 2013 May 14;49(39):4190-2. doi: 10.1039/c2cc37181b. Epub 2012 Nov 16.


Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.

Pasquier E, Tuset MP, Street J, Sinnappan S, MacKenzie KL, Braguer D, Andre N, Kavallaris M.

Angiogenesis. 2013 Apr;16(2):373-86. doi: 10.1007/s10456-012-9321-x. Epub 2012 Nov 10.


Functionalizing biodegradable dextran scaffolds using living radical polymerization: new versatile nanoparticles for the delivery of therapeutic molecules.

Duong HT, Hughes F, Sagnella S, Kavallaris M, Macmillan A, Whan R, Hook J, Davis TP, Boyer C.

Mol Pharm. 2012 Nov 5;9(11):3046-61. doi: 10.1021/mp300144y. Epub 2012 Oct 18.


TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members.

Bell JL, Malyukova A, Holien JK, Koach J, Parker MW, Kavallaris M, Marshall GM, Cheung BB.

PLoS One. 2012;7(5):e37470. doi: 10.1371/journal.pone.0037470. Epub 2012 May 21.

Supplemental Content

Loading ...
Support Center